Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer
-
Published:2024-09
Issue:
Volume:178
Page:117261
-
ISSN:0753-3322
-
Container-title:Biomedicine & Pharmacotherapy
-
language:en
-
Short-container-title:Biomedicine & Pharmacotherapy
Author:
Liu DajiaORCID,
Guo Lihui,
Waasdorp Cynthia,
Meijer Sybren L.,
Bootsma Sanne,
Oyarce Cesar,
Bijlsma Maarten F.,
van Laarhoven Hanneke W.M.
Reference63 articles.
1. Antiangiogenic therapy in oncology: current status and future directions;Jayson;Lancet,2016
2. Angiogenic signaling pathways and anti-angiogenic therapy for cancer;Liu;Signal Transduct. Target Ther.,2023
3. Tumor angiogenesis: causes, consequences, challenges and opportunities;Lugano;Cell Mol. Life Sci.,2020
4. Basic and Therapeutic Aspects of Angiogenesis Updated;Eelen;Circ. Res,2020
5. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial;Fuchs;Lancet,2014